Order Article Reprints

Beck O, Paret C, Russo A, Burhenne J, Fresnais M, Steimel K, Seidmann L, Wagner D-C, Vewinger N, Lehmann N, et al. Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma. Cancers. 2020; 12(4):793. https://doi.org/10.3390/cancers12040793

Beck, Olaf, Claudia Paret, Alexandra Russo, Jürgen Burhenne, Margaux Fresnais, Kevin Steimel, Larissa Seidmann, Daniel-Christoph Wagner, Nadine Vewinger, Nadine Lehmann, and et al. 2020. "Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma" Cancers 12, no. 4: 793. https://doi.org/10.3390/cancers12040793

Beck, O., Paret, C., Russo, A., Burhenne, J., Fresnais, M., Steimel, K., Seidmann, L., Wagner, D.-C., Vewinger, N., Lehmann, N., Sprang, M., Backes, N., Roth, L., Neu, M. A., Wingerter, A., Henninger, N., El Malki, K., Otto, H., Alt, F., ... Faber, J. (2020). Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma. Cancers, 12(4), 793. https://doi.org/10.3390/cancers12040793